09/09/2026 19:07
|
Medical, Health & Aged Care
HIGHLIGHTS
* H1 2026 revenues of €1.89 billion, up +3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area...